Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption
- 1 June 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (6) , 2138-2148
- https://doi.org/10.1128/aac.00461-07
Abstract
This article describes the population pharmacokinetics of rifampin in South African pulmonary tuberculosis patients. Three datasets containing 2,913 rifampin plasma concentration-time data points, collected from 261 South African pulmonary tuberculosis patients aged 18 to 72 years and weighing 28.5 to 85.5 kg and receiving regular daily treatment that included administration of rifampin (450 to 600 mg) for at least 10 days, were pooled. A compartmental pharmacokinetic model was developed using nonlinear mixed-effects modeling. Variability in the shape of the absorption curve was described using a flexible transit compartment model, in which a delay in the onset of absorption and a gradually changing absorption rate were modeled as the passage of drug through a chain of hypothetical compartments, ultimately reaching the absorption compartment. A previously described implementation was extended to allow its application to multiple-dosing data. The typical population estimate of oral clearance was 19.2 liters·h −1 , while the volume of distribution was estimated to be 53.2 liters. Interindividual variability was estimated to be 52.8% for clearance and 43.4% for volume of distribution. Interoccasional variability was estimated for CL/F (22.5%) and mean transit time during absorption (67.9%). The use of single-drug formulations was found to increase both the mean transit time (by 104%) and clearance (by 23.6%) relative to fixed-dose-combination use. A strong correlation between clearance and volume of distribution suggested substantial variability in bioavailability, which could have clinical implications, given the dependence of treatment effectiveness on exposure. The final model successfully described rifampin pharmacokinetics in the population studied and is suitable for simulation in this context.Keywords
This publication has 70 references indexed in Scilit:
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum SmearsAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2007
- Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2006
- Application of a Gamma Model of Absorption to Oral CyclosporinClinical Pharmacokinetics, 2001
- Bioavailablility of rifampicin in a separate formulation and fixed dose combination with iosniased NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosisCentral African Journal of Medicine, 1999
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Models for describing absorption rate and estimating extent of bioavailability: Application to cefetamet pivoxilJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Locally Weighted Regression: An Approach to Regression Analysis by Local FittingJournal of the American Statistical Association, 1988
- Clinical Pharmacokinetics of RifampicinClinical Pharmacokinetics, 1978